Russell Investments Group Ltd. trimmed its position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 20.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 25,897 shares of the biotechnology company’s stock after selling 6,682 shares during the period. Russell Investments Group Ltd. owned about 0.05% of Aimmune Therapeutics worth $532,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Schwab Charles Investment Management Inc. boosted its position in shares of Aimmune Therapeutics by 5.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 87,057 shares of the biotechnology company’s stock worth $1,892,000 after purchasing an additional 4,788 shares during the last quarter. Swiss National Bank boosted its position in shares of Aimmune Therapeutics by 17.5% in the 1st quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock worth $803,000 after purchasing an additional 5,500 shares during the last quarter. Credit Suisse AG boosted its position in shares of Aimmune Therapeutics by 14.1% in the 1st quarter. Credit Suisse AG now owns 42,445 shares of the biotechnology company’s stock worth $924,000 after purchasing an additional 5,248 shares during the last quarter. Palo Alto Investors LLC boosted its position in shares of Aimmune Therapeutics by 209.0% in the 1st quarter. Palo Alto Investors LLC now owns 1,173,498 shares of the biotechnology company’s stock worth $25,500,000 after purchasing an additional 793,771 shares during the last quarter. Finally, American International Group Inc. boosted its position in shares of Aimmune Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 1,070 shares during the last quarter. Hedge funds and other institutional investors own 72.90% of the company’s stock.

In related news, insider Douglas T. Sheehy sold 7,460 shares of the business’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $21.66, for a total value of $161,583.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Susan E. Barrowcliffe sold 6,110 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $22.00, for a total transaction of $134,420.00. Following the completion of the sale, the insider now directly owns 960 shares in the company, valued at approximately $21,120. The disclosure for this sale can be found here. In the last three months, insiders sold 236,860 shares of company stock worth $5,021,672. 24.56% of the stock is currently owned by insiders.

WARNING: “Russell Investments Group Ltd. Sells 6,682 Shares of Aimmune Therapeutics, Inc. (AIMT)” was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/russell-investments-group-ltd-sells-6682-shares-of-aimmune-therapeutics-inc-aimt/1576247.html.

Aimmune Therapeutics, Inc. (NASDAQ AIMT) traded up 0.69% on Wednesday, hitting $23.42. The stock had a trading volume of 79,411 shares. The company has a 50 day moving average of $23.31 and a 200 day moving average of $23.31. The company’s market capitalization is $1.18 billion. Aimmune Therapeutics, Inc. has a 12-month low of $14.11 and a 12-month high of $27.31.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01). On average, equities analysts expect that Aimmune Therapeutics, Inc. will post ($2.71) earnings per share for the current year.

AIMT has been the topic of several recent research reports. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. ValuEngine lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 27th. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Thursday, July 27th. Wedbush restated an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, July 24th. Finally, BidaskClub lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. Aimmune Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $32.50.

Aimmune Therapeutics Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.